The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus chemotherapy.
CHICAGO — The leading drug in biopharma’s hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
Akeso, Summit drug extends survival in closely watched lung cancer trial
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
Akeso lung cancer drug cuts death risk 34% in landmark trial
Akeso lung cancer drug trial raises hopes in US$20b market
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
A turning point for pancreatic cancer patients
Newly developed drug helps extend the lives of lung cancer patients in trial
New drug a ‘promising step forward’ for hard-to-treat lung cancer
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial,…
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important…
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's…
Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
